期刊
NEUROPSYCHOBIOLOGY
卷 67, 期 1, 页码 41-47出版社
KARGER
DOI: 10.1159/000343388
关键词
Serotonin; Genetic polymorphism; Genes; Major depression; Citalopram; Antidepressants; Psychosis
资金
- Ministry of Science and Innovation [IT2009-0016, SAF2008-05674-C03-00/03, FIS07/08152]
- Institute of Health Carlos III, GIBER of Mental Health (CIBERSAM)
- Comissionat per a Universitats I Recerca del DIUE of the Generalitat de Catalunya [2009SGR827]
- Ministero dell'Istruzione, dell'Universita e della Ricerca, Azioni Integrate Italia-Spagna, Pharmacogenetic of Antidepressants [IT08447BDE]
Background: Serotonergic genes have been widely investigated regarding antidepressant response in major depressive disorder (MDD) but results are still not univocal. Methods: 159 MDD patients treated with citalopram were genotyped and evaluated by the 21-item Hamilton Depression Rating Scale at the beginning and every 4 weeks during the 12-week follow-up. Four serotonin-related genetic variants were tested for association with treatment outcome: tryptophane hydroxylase 1 (TPH1) rs1800532, monoamine oxidase A ONTR, serotonin 2A receptor rs6311 and serotonin 2C receptor rs6318. The effect of these polymorphisms was tested both in the whole sample and in depressive subtypes with usually higher clinical severity: psychotic and melancholic MDD. Results: No effect on response, remission and symptom improvement was found for the four polymorphisms. However, rs1800532 was found to affect the outcome depending on the MDD subtype: the A allele predicted worse response both in MDD with psychotic (F-(6,F- 378) = 2.90; p = 0.009) and melancholic (F-(6,F- 381) = 2.86; p = 0.0097) features. Conclusions:The A allele at TPH1 rs1800532 may be associated with citalopram efficacy only in melancholic and psychotic MDD. These results suggest the usefulness of investigating the effect of genetic variants in conjunction with specific clinical features. Copyright (c) 2012S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据